AI claim denial management uses software to predict which claims will be denied before they are sent, fix the likely cause, sort denials that come back and draft appeals. It is one of the few hospital AI uses with an easily measured return, because recovered revenue shows up in the ledger. The catch is that payers respond, and the gains shrink as they do.
Ask a hospital chief financial officer where AI has paid for itself and the answer is rarely a diagnostic algorithm. It is usually something far less photogenic: the claims that come back unpaid.
Denials are a strange corner of healthcare. They are enormous in aggregate, tedious case by case, and mostly caused by boring problems. A missing authorisation number. A diagnosis code that does not match the procedure. A duplicate submission. Each one is small. Together they tie up staff, delay cash and, when nobody has time to chase them, simply become lost revenue.
That makes denial management an almost perfect target for AI. The data is structured, the outcome is binary (paid or not paid) and the return is counted in dollars rather than in contested clinical endpoints. It is no surprise that revenue cycle AI is booming while clinical AI still argues about trials.
But there is a second half to the story that vendors rarely put in the business case. Denials are a game with two players. The easiest AI win in the hospital is also the one where the other side adapts fastest.
How big is the claim denial problem?
Big enough that small percentages move serious money.
Premier, the hospital purchasing and analytics company, analysed 2022 claims data and reported in March 2024 that nearly 15% of claims submitted to private payers were initially denied. More than half of those denials, 54.3%, were eventually overturned and paid. Premier estimated that disputing denials cost providers an average of $43.84 per claim, or about $19.7 billion a year across the system. That is a lot of money spent to be paid for care that, in most contested cases, turned out to be payable.
Public data from the insurance side tells a similar story from another angle. KFF’s analysis of federal data on HealthCare.gov marketplace plans found that insurers denied about 20% of in-network claims in 2023, with rates ranging from 1% to 54% across insurers. Fewer than 1% of denied claims were appealed. The most common named reasons were administrative, such as missing information or duplicates, and a large share were coded simply as “other.”
Medicare Advantage has its own record. In a 2022 report, the HHS Office of Inspector General reviewed a sample of Medicare Advantage denials and estimated that 13% of prior authorization denials and 18% of payment denials concerned requests that met Medicare coverage and billing rules.
Two lessons stand out. First, a large share of denials are not clinical disagreements but paperwork failures, which is exactly what software can catch. Second, most denials are never challenged, which means the revenue sitting in the denial queue is often not lost to a payer’s decision but to a provider’s lack of time.
How does AI denial management actually work?
The tools fall into three groups, working at different points in the claim’s life.
Before submission, predictive models score each claim for denial risk, based on the payer, the service, the codes and the provider’s own history. High-risk claims are held and fixed: a missing modifier added, an authorisation attached, a diagnosis clarified. This is the highest-value stage, because a claim that is paid first time costs almost nothing to process.
After a denial, classification tools read the payer’s remittance codes and free-text explanations, sort denials by root cause and route them to the right team. The unglamorous gain here is prioritisation: working the highest-value, most winnable denials first instead of the oldest ones.
For appeals, generative models draft letters that pull the relevant clinical documentation, policy language and prior decisions into a single argument. What took a specialist forty minutes can be drafted in a few, leaving a human to check and send it.
All three are measurable in ways clinical AI rarely is. A hospital can compare first-pass payment rates, days in accounts receivable, appeal volumes and overturn rates before and after deployment, and turn the difference into dollars. That is why revenue cycle AI is often the first AI line item a board approves.
Why do the gains from denial AI fade?
Because the payer is not a static environment.
Every successful appeal is information to an insurer. If a hospital suddenly starts appealing 40% of denials instead of 5%, and winning half, the payer’s own systems will notice. The rational responses are well known: tighten documentation requirements, change medical policies, add pre-payment review for services where providers are winning, or automate the first pass of appeal review to keep costs down.
Insurers already use their own automation to process claims at scale. ProPublica reported in 2023 that Cigna’s medical directors, aided by a system called PxDx, denied more than 300,000 claims over two months in 2022, averaging 1.2 seconds per claim. Cigna disputes the characterisation, and the case is being litigated. But the broader point stands: the other side of the denial is a machine too, and it is being tuned by people whose job is to control spending.
This is where denial management differs from most hospital AI. A sepsis model does not face a counter-model trained to defeat it. A denial model does. The return on investment is therefore not a fixed number but a decaying one, strongest in the first year, when the hospital is catching errors the payer was happily profiting from, and weaker as the payer adjusts. Hospitals that budget as if year-one returns will continue indefinitely are setting up a painful conversation for year three.
A worked example: the appeal machine
Consider a hypothetical community hospital with $600 million in annual gross charges and an initial denial rate of 12%. Before any AI, its small denials team appeals only the largest claims. Many smaller denials are written off simply because nobody gets to them before the filing deadline.
In year one, the hospital deploys a pre-submission risk model and an appeal drafting tool. The first-pass denial rate falls to 9%, because obvious errors are fixed before claims go out. The share of remaining denials that are appealed triples. Net recovered revenue in the first year looks excellent: a meaningful percentage of net revenue, for a software cost that is a fraction of it.
In year two, two large commercial payers change course. One adds documentation requirements for the service lines where the hospital’s appeals are winning most often. The other extends pre-payment review to those services. The first-pass denial rate creeps back to 10.5%. Appeals now meet a more demanding bar. Recovered revenue is still positive, but lower, and the hospital’s appeal volume, now automated, has become a line item in the payers’ own cost reports.
In year three, the conversation shifts from “how much has the AI recovered?” to “how much would we lose if we turned it off?” That is a different, and more honest, measure of value.
The figures are illustrative. The dynamic, an early spike followed by adaptation, is what any two-sided market would predict.
Is the arms race framing unfair to denial AI?
The strongest counterargument is that most of what denial AI fixes is simply error, and error reduction does not provoke an arms race. If a claim is denied because an authorisation number was missing, and the hospital’s software now attaches it, the payer has no legitimate reason to fight back. Everyone saves money on rework. Payers themselves benefit from cleaner claims and have invested in electronic standards for exactly this reason.
That is correct for the administrative share of denials, and it is a large share. Pre-submission error correction is the least contested use of this technology, and hospitals should prioritise it for that reason.
The arms race lives elsewhere: in medical necessity, level-of-care and coding-intensity disputes, where the question is not whether a form was filled in but whether the payer should pay at all, or pay at a given level. That is where appeals win money, and where payers adapt. Most real-world denial AI does both kinds of work. Hospitals should separate the returns from each, because only one of them will last.
What this means for hospitals, payers and policymakers
For hospital finance leaders, the practical advice is to spend AI first where it reduces denials rather than where it wins them. Pre-submission fixes compound; appeal wins get competed away. Track first-pass payment rates by payer and service line, not just total recovered dollars, and expect the return on appeal automation to decline. Our piece on the questions hospitals ask too late when buying digital health is a useful checklist here, particularly on who owns the data and how vendor fees scale with “recovered” revenue.
Watch the vendor’s incentive, too. Contracts that pay a percentage of recovered revenue can reward volume of appeals over quality of claims. A vendor that makes more money when more claims are denied first is not fully aligned with a hospital that wants fewer denials.
For payers, the smarter response to provider automation is not to build a bigger wall but to reduce the cases that generate disputes. Publishing clear, stable coverage rules and fixing the reasons behind high overturn rates cost less than processing an ever-growing volume of machine-written appeals. We looked at how these incentives look from the other side in Value-Based Care, Seen From the Payer’s Chair.
For policymakers, the key figure is the overturn rate. When more than half of denials that are contested end up paid, as Premier’s data suggests for private payers, the initial denial is functioning less as a judgment and more as a toll on providers who lack the staff to appeal. Requiring public reporting of denial and overturn rates by insurer, as US federal rules are starting to do for prior authorization, would let everyone see whether automation on both sides is reducing errors or simply scaling the fight.
Frequently asked questions
What is AI denial management in healthcare?
It is the use of machine learning and generative AI across the claims process: predicting which claims are likely to be denied before submission, correcting the likely cause, classifying denials by root cause when they return and drafting appeal letters. Its goal is to increase the share of claims paid on first submission and recover more of the revenue that would otherwise be written off.
What are the most common reasons claims are denied?
Administrative issues account for a large share: missing or incorrect patient information, duplicate claims, missing prior authorisation, coding mismatches and late filing. KFF’s analysis of 2023 marketplace data also found many denials listed simply as “other.” Medical necessity denials are a smaller share by count but tend to involve higher-value claims and more contested appeals.
How much revenue can AI denial management recover?
It depends on the starting denial rate, payer mix and how many denials were previously abandoned. Hospitals with high write-offs often see large early gains. Those gains tend to shrink as errors are fixed and payers adjust their rules. Be wary of vendor figures that project first-year recovery rates indefinitely or that measure gross rather than net recovered revenue.
Do insurers use AI to deny claims?
Insurers use automated systems to process and review claims at scale, and several face lawsuits alleging that algorithms were used to deny claims or cut coverage without adequate individual review. Insurers say clinicians make coverage decisions. Some US states now require that medical necessity denials be made by licensed clinicians rather than by algorithms alone.
Should patients appeal a denied medical claim?
Usually it is worth asking. Fewer than 1% of denied marketplace claims were appealed in 2023, yet many appeals succeed. Ask the insurer for the specific reason in writing, and ask your clinician’s office whether a documentation fix or a letter of medical necessity would help. Deadlines apply, so act promptly.
Denial AI is the rare hospital AI project that pays for itself in a year. Plan on the second year being harder, and put most of the money into never needing to appeal in the first place.
Related on the GHC blog: Why Universal Health Coverage Stalls After the Pilot Phase and Primary Care Is the Cheapest Hospital Bed, But Only If You Close One.
Has your organisation seen payers change their rules after you automated appeals? Share what changed and how fast.
